Q2 Earnings Forecast for DYN Issued By HC Wainwright

Dyne Therapeutics, Inc. (NASDAQ:DYN) – Stock analysts at HC Wainwright issued their Q2 2027 earnings per share (EPS) estimates for Dyne Therapeutics in a research note issued on Friday, November 6th. HC Wainwright analyst A. Ghosh anticipates that the company will earn ($1.00) per share for the quarter. HC Wainwright has a “Buy” rating and a $32.00 price target on the stock. The consensus estimate for Dyne Therapeutics’ current full-year earnings is ($3.77) per share. HC Wainwright also issued estimates for Dyne Therapeutics’ Q3 2027 earnings at ($0.92) EPS, Q4 2027 earnings at ($0.62) EPS and FY2030 earnings at $0.84 EPS.

DYN has been the topic of a number of other research reports. Raymond James Financial reissued a “strong-buy” rating and set a $37.00 price target on shares of Dyne Therapeutics in a research report on Tuesday, September 8th. Stifel Nicolaus set a $37.00 price objective on Dyne Therapeutics in a report on Wednesday, September 30th. JPMorgan Chase & Co. lowered shares of Dyne Therapeutics from a “neutral” rating to an “underweight” rating and lowered their price objective for the stock from $17.00 to $10.00 in a research note on Wednesday, September 9th. Jefferies Financial Group reiterated a “buy” rating and set a $50.00 target price on shares of Dyne Therapeutics in a report on Wednesday, September 30th. Finally, Royal Bank Of Canada dropped their target price on shares of Dyne Therapeutics from $35.00 to $30.00 and set an “outperform” rating on the stock in a report on Wednesday, September 9th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $31.29.

Dyne Therapeutics Price Performance

Shares of DYN stock opened at $17.92 on Monday. Dyne Therapeutics has a twelve month low of $14.00 and a twelve month high of $27.31. The stock has a market capitalization of $3.36 billion, a price-to-earnings ratio of -4.94 and a beta of 1.22. The stock has a fifty day simple moving average of $17.42 and a two-hundred day simple moving average of $19.34. The company has a current ratio of 12.99, a quick ratio of 12.99 and a debt-to-equity ratio of 0.21.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings data on Thursday, November 5th. The company reported ($1.06) EPS for the quarter, missing the consensus estimate of ($0.91) by ($0.15). During the same period in the prior year, the firm posted ($0.76) earnings per share.

Insider Buying and Selling

In related news, Director Jason Rhodes sold 2,160,516 shares of the firm’s stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $25.00, for a total transaction of $54,012,900.00. Following the sale, the director owned 428,946 shares of the company’s stock, valued at $10,723,650. This trade represents a 83.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John Cox sold 5,658 shares of Dyne Therapeutics stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $18.88, for a total value of $106,823.04. Following the completion of the transaction, the chief executive officer owned 357,507 shares in the company, valued at $6,749,732.16. This trade represents a 1.56% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 2,598,706 shares of company stock valued at $65,432,671. Company insiders own 9.46% of the company’s stock.

Institutional Investors Weigh In On Dyne Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. purchased a new position in Dyne Therapeutics in the second quarter worth $275,500,000. Jupiter Topco LLC acquired a new position in shares of Dyne Therapeutics during the second quarter worth $266,634,000. Bank of America Corp DE purchased a new stake in shares of Dyne Therapeutics during the 2nd quarter valued at $49,604,000. Palo Alto Investors LP purchased a new stake in shares of Dyne Therapeutics during the 2nd quarter valued at $36,591,441. Finally, Perceptive Advisors LLC lifted its holdings in shares of Dyne Therapeutics by 34.2% during the 1st quarter. Perceptive Advisors LLC now owns 4,668,839 shares of the company’s stock valued at $84,646,000 after purchasing an additional 1,189,895 shares during the last quarter. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Trending Headlines about Dyne Therapeutics

Here are the key news stories impacting Dyne Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated its Buy rating and $32 price target. It also raised its Q4 2026 EPS estimate to a loss of $0.95 per share from $1.01, a modest improvement. Dyne Therapeutics analyst estimates
• Neutral Sentiment: A short-interest update reported zero shares sold short and a 0.0-day short-interest ratio, despite describing short interest as having increased significantly. The figures are contradictory, so they offer little reliable indication of investor positioning.
• Negative Sentiment: HC Wainwright lowered its projected EPS for FY2027, FY2028 and FY2029, implying larger expected losses in those years. Its FY2026 estimate also edged lower; the company is expected to remain loss-making. Dyne Therapeutics analyst estimates

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company developing therapies for genetically driven muscle diseases. Its research uses the FORCE platform, which is designed to deliver oligonucleotide medicines to muscle tissue. The company’s programs include DYNE-101 for myotonic dystrophy type 1 and DYNE-251 for Duchenne muscular dystrophy in patients whose genetic mutations are amenable to exon 51 skipping. Dyne has also pursued a program for facioscapulohumeral muscular dystrophy. Its therapies remain in development, and the company does not have an approved product.